Description
This session takes a comprehensive, case-based look at the journey of a patient with Type 2 Diabetes, from initial diagnosis to the development and management of complications. It will highlight key clinical decision points, including early screening, glycemic control strategies, and risk assessment for microvascular and macrovascular complications. Through real-life scenarios, the discussion will emphasize individualized treatment plans, lifestyle interventions, and the use of newer antidiabetic therapies. The aim is to provide practical insights that improve long-term outcomes and prevent disease progression in diabetic patients.
Summary Listen
- Diabetes is a global issue influenced by lifestyle. There isn't a universal solution or expert, but insights from top centers can be helpful, even though many worldwide lack proper resources due to funding limitations and limited access to healthcare. The future of diabetes management is promising due to ongoing research and advancements.
- Key areas in type 2 diabetes management include metabolic obesity (understanding that not all overweight individuals have metabolic problems), diet (emphasizing its crucial role regardless of cultural or dietary practices), and drug therapies (essential when lifestyle and dietary changes are insufficient). Advanced practices, where resources are plentiful, aim for optimal patient control by 2025.
- Abdominal obesity is a common type of type 2 diabetes, especially in affluent regions. South Asians may have different waist circumference standards, but raised waist circumference increases vulnerability to metabolic diseases like high blood pressure, gestational diabetes, and dyslipidemia. These conditions raise the risk of heart attacks and strokes at a younger age, necessitating early assessment of heart and kidney health.
- Two patient cases illustrate the evolution of diabetes care. The first case involved a young businessman with a strong family history of cardiovascular disease. Despite aggressive treatment, his condition progressed, emphasizing the need for earlier and more intensive interventions. Modern therapies are showing promise but are not universally accessible.
- The second case involved a patient with a history of stenting. He had abnormal liver functions and had been put on Victosa. His case highlights the challenges of managing multiple health issues alongside diabetes, including liver fibrosis. GLP-1 agonists have demonstrated a transformative effect on metabolic obesity and liver fibrosis.
- Thin diabetic patients may have late onset type 1 diabetes that requires insulin treatments. Diabetes management has to take into consideration cultural and personal beliefs and diets. New developments in diabetes care will include the use of GLP-1 agonists for metabolic obesity, liver steatosis and liver fibrosis, and cholesterol and lipoproteins as measurements in the clinic.
Sample Certificate
About the Speakers
Dr. Ralph Abraham
Consultant Physician in Endocrinology, Diabetes, and Lipid Disorders London Medical, London, United Kingdom
Comments
Comments
You must be logged in to leave a comment.